Vitamin D status in gastrointestinal and liver disease

Current Opinion in Gastroenterology

Volumn 24, Issue 2, 2008, Pages 176-183

  Pappa, Helen M ^a,b   Bern, Elana ^a,b   Kamin, Daniel ^a,b   Grand, Richard J ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Celiac disease; Cystic fibrosis; Gastrointestinal disease; Inflammatory bowel disease; Liver disease; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ERGOCALCIFEROL; VITAMIN D;

BODY MASS; BONE DENSITY; CELIAC DISEASE; CLINICAL FEATURE; CROHN DISEASE; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE SYSTEM; LIVER DISEASE; METABOLIC BONE DISEASE; NONHUMAN; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

BONE DISEASES; DIGESTIVE SYSTEM DISEASES; GASTROINTESTINAL DISEASES; HUMANS; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASES; LIVER DISEASES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 40049084643     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f4d2f3     Document Type: Review

References (131)

1. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80 (6 Suppl):1678S-1688S.
2. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 1995; 61 (3 Suppl):638S-645S.
3. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67:373-378.
4. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995; 53:579-582.
5. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16:200-257.
6. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281. A comprehensive and important review of this topic.
7. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
8. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
9. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275:20959-20962.
10. Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188:997-1001.
11. Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J Cell Biochem 2006; 97:226-232. An intriguing approach to a challenging problem.
12. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175-179.
13. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96:3540-3545.
14. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479-487.
15. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279:16754-16766.
16. van Driel M, Koedam M, Buurman CJ, et al. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 2006; 99:922-935.
17. Kitazawa S, Kajimoto K, Kondo T, et al. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 2003; 89:771-777.
18. Kondo T, Kitazawa R, Maeda S, et al. 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res 2004; 19:1411-1419.
19. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81:353-373. An important review of the consequences of suboptimal vitamin D stores in the general population.
20. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84:18-28. An important review of the evidence that will lead to increases in the recommended vitamin D daily intake even in healthy populations in the near future.
21. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713-716.
22. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22:142-146.
23. Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68:854-858.
24. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89:5387-5391.
25. Lehtonen-Veromaa M, Mottonen T, Nuotio I, et al. The effect of conventional vitamin D(2) supplementation on serum 25(OH)D concentration is weak among peripubertal Finnish girls: a 3-y prospective study. Eur J Clin Nutr 2002; 56:431-437.
26. Lehtonen-Veromaa M, Mottonen T, Irjala K, et al. Vitamin D intake is low and hypovitaminosis D common in healthy 9- to 15-year-old Finnish girls. Eur J Clin Nutr 1999; 53:746-751.
27. Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124:400-406.
28. Simonelli C, Weiss TW, Morancey J, et al. Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 2005; 21:1069-1074.
29. Antoniucci DM, Vittinghoff E, Blackwell T, et al. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 2005; 90:4566-4572.
30. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77:204-210.
31. Barger-Lux MJ, Heaney RP. Effects of above average summer sun exposure on serum 25-hydroxyvitamin D and calcium absorption. J Clin Endocrinol Metab 2002; 87:4952-4956.
32. Vieth R, Kimball S, Hu A, et al. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004; 3:8.
33. Tangpricha V, Koutkia P, Rieke SM, et al. Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. Am J Clin Nutr 2003; 77:1478-1483.
34. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, FaNB, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, DC: The National Academies Press; 1997.
35. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229:1136-1142.
36. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996; 93:7861-7864.
37. Cantorna MT, Humpal-Winter J, DeLuca HF. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr 1999; 129:1966-1971.
38. Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979; 29(9 Pt 1):1228-1235.
39. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004; 55:65-71.
40. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60-65.
41. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128:68-72.
42. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004; 50:72-77.
43. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17:2386-2392.
44. Cantorna MT, Munsick C, Bemiss C, et al. 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130:2648-2652.
45. Mathieu C, Waer M, Laureys J, et al. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37:552-558.
46. Giulietti A, Gysemans C, Stoffels K, et al. Vitamin D deficiency in early life accelerates type 1 diabetes in nonobese diabetic mice. Diabetologia 2004; 47:451-462.
47. Casteels K, Bouillon R, Waer M, et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Curr Opin Nephrol Hypertens 1995; 4:313-318.
48. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358:1500-1503.
49. Siffledeen JS, Siminoski K, Steinhart H, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol 2003; 17:473-478.
50. McCarthy D, Duggan P, O'Brien M, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther 2005; 21:1073-1083.
51. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol 2004; 39:527-533.
52. Mezquita Raya P, Munoz Torres M, Lopez Rodriguez F, et al. Prevalence of vitamin D deficiency in populations at risk for osteoporosis: impact on bone integrity. Med Clin (Barc) 2002; 119:85-89.
53. Jahnsen J, Falch JA, Mowinckel P, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37:192-199.
54. Andreassen H, Rix M, Brot C, et al. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand J Gastroenterol 1998; 33:1087-1093.
55. Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609-614.
56. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92:1157-1163.
57. Harries AD, Brown R, Heatley RV, et al. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 1985; 26:1197-1203.
58. Driscoll RH Jr, Meredith SC, Sitrin M, et al. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252-1258.
59. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996; 239:131-137.
60. Sentongo TA, Semaeo EJ, Stettler N, et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002; 76:1077-1081.
61. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902-911.
62. Issenman RM, Atkinson SA, Radoja C, et al. Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17:401-406.
63. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006; 118:1950-1961. An important new study of the topic of the pathogenesis of hypovitaminosis D in childhood IBD.
64. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158:531-537.
65. Lo CW, Paris PW, Clemens TL, et al. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr 1985; 42:644-649.
66. Vogelsang H, Schofl R, Tillinger W, et al. 25-Hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency. Wien Klin Wochenschr 1997; 109:678-682.
67. Mezquita-Raya P, Munoz-Torres M, Luna JD, et al. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res 2001; 16:1408-1415.
68. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116:634-639.
69. Bhattoa HP, Bettembuk P, Ganacharya S, et al. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in community dwelling postmenopausal Hungarian women. Osteoporos Int 2004; 15:447-451.
70. Serhan E, Holland MR. Relationship of hypovitaminosis D and secondary hyperparathyroidism with bone mineral density among UK resident Indo-Asians. Ann Rheum Dis 2002; 61:456-458.
71. Lehtonen-Veromaa MK, Mottonen TT, Nuotio IO, et al. Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-y prospective study. Am J Clin Nutr 2002; 76:1446-1453.
72. Valimaki VV, Alfthan H, Lehmuskallio E, et al. Vitamin D status as a determinant of peak bone mass in young Finnish men. J Clin Endocrinol Metab 2004; 89:76-80.
73. Abitbol V, Roux C, Guillemant S, et al. Bone assessment in patients with ileal pouch-anal anastomosis for inflammatory bowel disease. Br J Surg 1997; 84:1551-1554.
74. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247:63-70.
75. Scharla SH, Minne HW, Lempert UG, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol 1994; 102:44-49.
76. von Scheven E, Gordon CM, Wypij D, et al. Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study. J Pediatr Endocrinol Metab 2006; 19:821-830.
77. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev 2002; 23:763-786.
78. Shany S, Levy Y, Lahav-Cohen M. The effects of 1alpha,24(S)- dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression. Steroids 2001; 66:319-325.
79. Cohen ML, Douvdevani A, Chaimovitz C, et al. Regulation of TNF-alpha by 1alpha,25-dihydroxyvitamin D3 in human macrophages from CAPD patients. Kidney Int 2001; 59:69-75.
80. Lange U, Jung O, Teichmann J, et al. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 2001; 12:1031-1035.
81. Lange U, Teichmann J, Strunk J, et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 2005; 16:1999-2004.
82. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:961-968.
83. Verstraeten A, Dequeker J, Nijs J, et al. Prevention of postmenopausal bone loss in rheumatoid arthritis patients: a two-year prospective study. Clin Exp Rheumatol 1989; 7:351-358.
84. Brohult J, Jonson B. Effects of large doses of calciferol on patients with rheumatoid arthritis: a double-blind clinical trial. Scand J Rheumatol 1973; 2:173-176.
85. Yamauchi Y, Tsunematsu T, Konda S, et al. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi 1989; 29:11-24.
86. Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr 2006; 148:461-466. A novel conceptual approach to bone metabolism in Crohn's disease in children.
87. Zhu Y, Mahon BD, Froicu M, et al. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35:217-224.
88. Stio M, Treves C, Celli A, et al. Synergistic inhibitory effect of cyclosporin A and vitamin D derivatives on T-lymphocyte proliferation in active ulcerative colitis. Am J Gastroenterol 2002; 97:679-689.
89. Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 1992; 33:1660-1663.
90. Kaukinen K, Partanen J, Maki M, et al. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol 2002; 97:695-699.
91. Rewers M. Epidemiology of celiac disease: what are the prevalence, incidence, and progression of celiac disease? Gastroenterology 2005; 128 (4 Suppl 1):S47-51.
92. Marsh MN. Gluten, major histocompatibility complex, and the small intestine: a molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102:330-354.
93. Kupper C. Dietary guidelines and implementation for celiac disease. Gastroenterology 2005; 128 (4 Suppl 1):S121-S127.
94. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131:1981-2002.
95. Corazza GR, Di Sario A, Cecchetti L, et al. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996; 18:525-530.
96. Valdimarsson T, Toss G, Lofman O, et al. Three years' follow-up of bone density in adult coeliac disease: significance of secondary hyperparathyroidism. Scand J Gastroenterol 2000; 35:274-280.
97. Kinsey L, Burden ST, Bannerman E. A dietary survey to determine if patients with coeliac disease are meeting current healthy eating guidelines and how their diet compares to that of the British general population. Eur J Clin Nutr 2007; 15 August [Epub ahead of print]. This is a search for dietary patterns that alter nutrient intake in patients with celiac disease.
98. Mariani P, Viti MG, Montuori M, et al. The gluten-free diet: a nutritional risk factor for adolescents with celiac disease? J Pediatr Gastroenterol Nutr 1998; 27:519-523.
99. Colston KW, Mackay AG, Finlayson C, et al. Localisation of vitamin D receptor in normal human duodenum and in patients with coeliac disease. Gut 1994; 35:1219-1225.
100. Kalayci AG, Kansu A, Girgin N, et al. Bone mineral density and importance of a gluten-free diet in patients with celiac disease in childhood. Pediatrics 2001; 108:E89.
101. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795-841.
102. Kemppainen T, Kroger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. Bone 1999; 24:249-255.
103. Taranta A, Fortunati D, Longo M, et al. Imbalance of osteoclastogenesisregulating factors in patients with celiac disease. J Bone Miner Res 2004; 19:1112-1121.
104. Fiore CE, Pennisi P, Ferro G, et al. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm Metab Res 2006; 38:417-422.
105. Mora S. Celiac disease: a bone perspective. J Pediatr Gastroenterol Nutr 2003; 37:409-411.
106. Kavak US, Yuce A, Kocak N, et al. Bone mineral density in children with untreated and treated celiac disease. J Pediatr Gastroenterol Nutr 2003; 37:434-436.
107. Pazianas M, Butcher GP, Subhani JM, et al. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. Osteoporos Int 2005; 16:56-63.
108. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888-1896.
109. Elkin SL, Vedi S, Bord S, et al. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med 2002; 166:1470-1474.
110. Schulze KJ, O'Brien KO, Germain-Lee EL, et al. Calcium kinetics are altered in clinically stable girls with cystic fibrosis. J Clin Endocrinol Metab 2004; 89:3385-3391.
111. Boyle MP, Noschese ML, Watts SL, et al. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 172:212-217.
112. Hanly JG, McKenna MJ, Quigley C, et al. Hypovitaminosis D and response to supplementation in older patients with cystic fibrosis. Q J Med 1985; 56:377-385.
113. Kelly E, Rafii M, Pencharz P, Tullis E. Effect of vitamin D supplementation on low serum 25-hydroxyvitamin D in adults with cystic fibrosis. Pediatr Pulmonol 2002; 24 (Suppl):344.
114. Stephenson A, Brotherwood M, Robert R, et al. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr 2007; 85:1307-1311. An important paper that emphasizes the efficacy of vitamin D3 in repleting 25OHD levels in CF.
115. Heubi JE, Hollis BW, Specker B, et al. Bone disease in chronic childhood cholestasis. I: Vitamin D absorption and metabolism. Hepatology 1989; 9:258-264.
116. Klein GL, Soriano H, Shulman RJ, et al. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant 2002; 6:136-140.
117. Jung RT, Davie M, Siklos P, et al. Vitamin D metabolism in acute and chronic cholestasis. Gut 1979; 20:840-847.
118. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5:513-520. A valuable study of this topic.
119. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000; 95:2343-2351.
120. Guthery SL, Pohl JF, Bucuvalas JC, et al. Bone mineral density in long-term survivors following pediatric liver transplantation. Liver Transpl 2003; 9:365-370.
121. Argao EA, Balistreri WF, Hollis BW, et al. Effect of orthotopic liver transplantation on bone mineral content and serum vitamin D metabolites in infants and children with chronic cholestasis. Hepatology 1994; 20:598-603.
122. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46:1271-1278. An excellent review of the topic.
123. Shiomi S, Nishiguchi S, Kubo S, et al. Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 2002; 97:978-981.
124. Kurihara N, Roodman GD. Interferons-alpha and -gamma inhibit interleukin-1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. J Interferon Res 1990; 10:541-547.
125. Mobarhan SA, Russell RM, Recker RR, et al. Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology 1984; 4:266-273.
126. Floreani A, Carderi I, Ferrara F, et al. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig Liver Dis 2007; 39:544-548.
127. Argao EA, Specker BL, Heubi JE. Bone mineral content in infants and children with chronic cholestatic liver disease. Pediatrics 1993; 91:1151-1154.
128. Diamond T, Stiel D, Mason R, et al. Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. J Clin Endocrinol Metab 1989; 69:1234-1239.
129. Crosbie OM, Freaney R, McKenna MJ, et al. Predicting bone loss following orthotopic liver transplantation. Gut 1999; 44:430-434.
130. Guichelaar MM, Kendall R, Malinchoc M, et al. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12:1390-1402. An important study of the natural history of the effect of liver disease and liver transplantation on bone mineral metabolism.
131. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35:126-131.